Product Description
Innovent Biologics is developing IBI-311, an intravenous injection drug candidate. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05480579?term=IBI-311&draw=2&rank=1)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innovent Biologics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Graves Disease|Graves Ophthalmopathy|Thyroid Eye Disease
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CIBI311A202 | P2 |
Active, not recruiting |
Graves Ophthalmopathy|Graves Disease|Thyroid Eye Disease |
2025-08-22 |
|
CIBI311A301 | P3 |
Recruiting |
Graves Ophthalmopathy|Thyroid Eye Disease|Graves Disease |
2025-02-15 |
66% |
CIBI311A201 | P3 |
Completed |
Thyroid Eye Disease|Graves Disease|Graves Ophthalmopathy |
2023-12-20 |
55% |
CIBI311A101 | P1 |
Completed |
Healthy Volunteers |
2022-11-23 |
28% |